Retraction Note: Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Withdrawal Notice: Assessment of Ovarian Function and Metabolic Parameters in Women with Polycystic Ovary Syndrome Following d-Chiro-Inositol Treatment

  • By

  • Antonio Simone Laganà

  • Luisa Barbaro

  • Alfonsa Pizzo

  • July 15, 2026

Share

Objective:

To assess ovarian function and metabolic parameters in women with Polycystic Ovary Syndrome following d-Chiro-Inositol treatment.

Approach:
  • Study Design: The study aimed to evaluate the effects of d-Chiro-Inositol on ovarian function and metabolic parameters.
Key Findings:
  • Concerns were raised regarding similarities in data reported in this article and another article by the same authors.
  • Some values in Table 1 for the pre- and post-treatment d-Chiro-inositol groups appeared highly similar.
  • Statistics reported in Table 1 were found to be incorrect.
Interpretation:

The Editor-in-Chief lost confidence in the results and conclusions of the study due to the raised concerns.

Limitations:
  • The authors did not provide satisfactory responses to the concerns raised.
  • Raw data was not supplied by the authors.
Conclusion:

The article has been retracted due to issues with data integrity and lack of author response.

Sources:

Original Source(s)

Retraction Note: Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol

  • by Antonio Simone Laganà, Luisa Barbaro, Alfonsa Pizzo

  • July 15, 2026

Related Content

Beyond BMI: insulin resistance emerges as the key metabolic correlate of AMH in PCOS

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

Ovarian intelligence: AI applications leveraging AMH and inhibin B